How Long Should You Stay on GLP-1 | MetaGO

How Long Should You Stay on a GLP-1? The Chronic Disease Framing

Table of Contents

Quick Answer
How long to stay on Mounjaro or any GLP-1 has no fixed answer. Doctors treat it as long-term care for a chronic condition. In trials, people who stopped regained between half and two-thirds of their lost weight within a year. Many continue for years at a steady or lower maintenance dose, reviewed regularly with a doctor.

Obesity as a Chronic Disease

Obesity is a long-term condition, and the body actively defends the heaviest weight it has settled at. That single fact decides how long any GLP-1 treatment should last.

Weight is run by a conversation between the gut, fat tissue and the brain. After weight loss, hunger hormones climb and fullness signals fade, and research has found this shift can last at least a year. The body reads a slimmer version of itself as a food shortage and nudges you to eat your way back.

India put this view on paper in 2025. The Revised Definition of Obesity in Asian Indians by Misra and colleagues sets the starting line at a BMI above 23, well below the Western cut-off of 30, and brings waist size into the diagnosis.

Under Indian guidance, a waist above 90 cm in men or 80 cm in women counts as excess belly fat. The definition then splits obesity into two stages: extra fat without harm yet, and extra fat that has started to show up as rising blood sugar, high blood pressure or knees that complain on the stairs.

In 2021, an estimated 25 crore Indians had generalised obesity, and about 35 crore carried excess abdominal fat.

How Long Do People Stay on GLP-1s?

People are staying on longer than they used to, though many still stop within the first year.

A 2026 study by Marshall and colleagues, Trends in 1-Year Persistence and Adherence, tracked 33,607 American adults without diabetes who started a weight-loss GLP-1 between 2021 and mid-2024. Of those who began in 2021, only about one in three were still on treatment a year later. For those who began in early 2024, the figure had nearly doubled to about six in ten.

The authors link part of that rise to medicine shortages easing, with better dose step-ups and side-effect support also likely to help. Stomach side effects remain a frequent reason people quit.

No published Indian study has tracked this yet, so these Western numbers are the closest guide available.

So how long should you stay on Mounjaro, or any GLP-1, if you follow the trials rather than the averages? Weight loss tends to level off somewhere between the first and second year, and an open-ended maintenance phase follows. Mounjaro’s approved use in India is described as chronic weight management, which is the label’s way of saying the same thing.

Is It Lifelong?

For many people it becomes long-term, though nobody has to sign up for life on day one. The decision gets made, and remade, at each review.

Blood pressure tablets offer the clearest comparison. When BP settles at 125/80 on a tablet, no doctor calls that a cure; the tablet is the reason it settled. GLP-1 medicines act on appetite in the same way, and the effect lasts as long as the medicine does.

The SURMOUNT-4 trial tested this head-on. After 36 weeks on tirzepatide (the medicine in Mounjaro), 670 adults were split: half continued, and half were switched to a dummy injection without knowing it.

Over the next year, the switched group regained roughly half of what they had lost, while those who continued kept losing a little more. Put simply, someone who had lost 16 kg could expect about 8 kg back within a year of stopping.

Stopping is not a cliff for everyone. Nearly half of the switched group still held at least a 10% loss from where they started, though trials have not yet found a reliable way to predict who those people will be.

Real-world records look gentler than trials. A study found that people who stopped within a year of starting had regained little on average twelve months later, but they had lost less to begin with, and close to half had restarted or switched to another medicine.

Long-Term Safety Data So Far

Medicines that mimic the gut hormone GLP-1 (GLP-1 receptor agonists) have about two decades of use in type 2 diabetes, and weight-loss doses have been studied for up to four years.

The longest semaglutide weight trial is SELECT, which followed 17,604 adults with heart disease and excess weight, none with diabetes. Weight loss on semaglutide (the medicine in Wegovy and Ozempic) held for up to four years, and serious adverse events were less frequent than on placebo.

The same trial is candid about the other side. More people stopped the active medicine than the placebo, and stopping was more common among those who started at a lower weight.

Day to day, the familiar list of Ozempic side effects applies across the class: nausea, loose motions, constipation and acid reflux. These usually peak during dose increases and settle within weeks for most people.

Rarer problems include gallstones and inflammation of the pancreas (pancreatitis). Prescribing labels also advise against these medicines for anyone with a personal or family history of a rare thyroid cancer called medullary thyroid carcinoma.

Muscle deserves attention too. Fast weight loss takes some muscle with it, which is why protein at every meal (a katori of dal, paneer, eggs or curd) and regular strength training matter more in year three than in month three.

What the data cannot tell us yet is how these medicines behave over 15 or 20 years. That gap is real, and it is one reason long-term use stays under a doctor’s eye.

The Maintenance Phase

Maintenance begins when the weight stops falling, and the goal switches from losing kilos to keeping them off.

One detail confuses many people. On a prescribing label, the “maintenance dose” is simply the dose reached after the step-up weeks, and it is often the highest dose. In clinic conversation, the “maintenance phase” means the long stretch after weight has plateaued.

You can usually tell the loss phase is over when the scale has barely moved for a couple of months despite steady habits. Reviews then shift from “how much more?” to “how do we hold this?”

What a doctor tracks also changes. Waist size, HbA1c, blood pressure, lipids and strength start to matter more than the weekly weigh-in.

Lower doses and longer intervals

Stepping down to a lower dose is the one way of easing off that has been tested in a randomised trial.

The SURMOUNT-MAINTAIN trial, published in 2026, took 378 adults who had lost weight on full-dose tirzepatide. For one year, they either stayed on full dose, stepped down to a lower dose, or switched to placebo.

Full dose held the weight almost completely, and the lower dose kept most of it. About one in four on the lower dose regained half or more of their loss, against two in three on placebo and fewer than one in ten on full dose.

In plain terms, a lower dose works for many people but not all, so a step-down needs close weight checks in the months that follow.

Spacing injections further apart has far thinner support. Most held their weight over about eight months, and four others went back to weekly doses after their weight crept up.

That is an observation, untested in any randomised trial and outside the prescribing label. Changing the interval is a call only your doctor should make.

Maintenance routeWhat the evidence shows so far
Continue the same doseWeight held for up to four years in the longest trial
Step down to a lower doseOne randomised trial: most people kept most of their loss
Space doses further apartOne small observational report; not tested in trials
Stop completelyHalf to two-thirds of lost weight returned within a year in trials

Planned Breaks: What Happens

A short pause is sometimes medically necessary, but a long one usually costs weight.

The STEP 1 trial extension followed adults for a year after they stopped semaglutide and the lifestyle programme that came with it. They regained about two-thirds of the weight they had lost, and most of their improvements in blood pressure, blood sugar and cholesterol drifted back towards where they began.

For someone who had lost 15 kg, that means about 10 kg returning in twelve months.

A 2026 review of 37 studies put the pace of regain after stopping the newer medicines at about 0.8 kg a month, faster than after ending a diet programme.

Good reasons for a planned break do exist. Doctors usually advise stopping before trying to conceive, and surgery matters too: these medicines slow the stomach, so your surgeon and anaesthetist need to know. A severe stomach bug with vomiting, or side effects that will not settle, can also justify a pause.

Wedding season or a long trip abroad is rarely a good reason to stop. A doctor can usually plan for it, including how to carry a medicine that needs refrigeration.

If a break is planned, keep the steps simple:

  1. Agree the stop date with your doctor first.
  2. Note your weight and waist on that day.
  3. Check both once a week while off the medicine.
  4. Decide in advance how much regain should trigger a call.
  5. Ask how restarting will work. Labels advise checking with your doctor after a gap of two weeks or more, and restarting often begins at a lower dose to rebuild tolerance.

Cost Over Time

The real cost of a GLP-1 is set by how many years you take it, so plan for the duration rather than the first month.

The long-run total depends less on the first prescription and more on what happens in maintenance. A lower maintenance dose, where it holds your weight, reduces the medicine you need, and reviews become less frequent once weight is stable, though periodic blood tests continue.

Stopping carries its own cost. Regained weight often brings back the blood sugar and blood pressure problems that treatment had eased, and restarting usually means repeating the step-up weeks, side effects included.

One safety rule holds throughout: buy only against a valid prescription from a licensed pharmacy. Unregulated imports and online copies sold without a prescription carry real risks of wrong dosing and contamination.

Deciding With Your Doctor

How long you stay on a GLP-1 is a decision you revisit at every review, using a few clear markers.

Question to raiseWhy it matters
Has my weight plateaued?It marks the move from the loss phase to maintenance
Have my sugar, BP, lipids and waist improved?These gains tend to fade if the weight returns
Am I holding on to muscle?Lost muscle means less strength and stamina for daily life
Are the side effects manageable?Side effects are a leading reason people stop
Could a lower dose hold my weight?One trial supports stepping down for many people
If I stop, what is the plan?A regain trigger and a restart plan catch problems early

Mounjaro, Wegovy and Ozempic are prescription-only medicines in India. The dose, the duration and any change to either belong in a doctor-guided plan, reviewed as your body and your goals change.

Conclusion
GLP-1 medicines keep working while you take them, because obesity is a chronic condition the body defends. Trials show most people regain a large share of lost weight within a year of stopping, while those who continue hold their results for years. For many people the practical path is a long maintenance phase, sometimes at a lower dose, with breaks only for good medical reasons. How long that lasts is a decision to revisit with your doctor at every review.

Frequently Asked Questions

1. How long do I need to stay on a GLP-1?

Most doctors plan for at least the weight-loss phase, which usually runs through the first one to two years, followed by a maintenance phase with no fixed end date. Trials show that stopping early often brings much of the weight back, so the timeline is reviewed with your doctor rather than set in advance.

2. Is this a lifelong medication?

It can be, though it does not have to be decided on day one. Obesity behaves like a chronic condition, and trials show regain of half to two-thirds of lost weight within a year of stopping. Some people step down to a lower dose or take a supervised break, and that choice is made with a doctor at each review.

3. Is long-term use safe?

The evidence so far is reassuring. GLP-1 medicines have been used in type 2 diabetes for about two decades, and one weight-loss trial followed adults for up to four years with fewer serious adverse events than placebo. Stomach side effects are common early on, and rare risks such as gallstones and pancreatitis need medical monitoring.

4. Can I take a planned break?

Yes, when there is a good medical reason, such as planning a pregnancy, upcoming surgery or side effects that will not settle. Expect some weight to return, and agree with your doctor beforehand how you will track it. After a longer gap, restarting often begins at a lower dose.

5. What happens at the maintenance stage?

Maintenance starts once weight stops falling, and the goal shifts to holding the loss. On prescribing labels, the maintenance dose simply means the dose reached after the step-up weeks. 

Reviews focus on waist, blood sugar, blood pressure, lipids and muscle, and a 2026 trial found that stepping down to a lower dose kept most of the weight off for many people. Any dose change is a doctor’s decision.

Medical Disclaimer
This article is for general education and does not replace advice from a qualified doctor. GLP-1 medicines, including Mounjaro, Wegovy and Ozempic, are prescription-only in India and should be started, adjusted or stopped only under medical supervision. Individual results and side effects vary. If you have symptoms or questions about your treatment, speak to your doctor.
  1. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S; India Obesity Commission. Revised definition of obesity in Asian Indians living in India. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2025;19(1):102989. https://doi.org/10.1016/j.dsx.2024.102989
  2. Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY. Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. Journal of Managed Care & Specialty Pharmacy. 2026;32(3):281-291. https://doi.org/10.18553/jmcp.2026.32.3.281
  3. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
  4. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024;30(7):2049-2057. https://doi.org/10.1038/s41591-024-02996-7
  5. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2026;407(10545):2305-2318. https://doi.org/10.1016/S0140-6736(26)00656-2
  6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725
Picture of Dr. Kaushal Patel

Dr. Kaushal Patel

MBBS, MD (Medicine), [Cardiologist Specialist in Diabetology & Obesity Management]